Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Alexander Egle; Michael Steurer; Thomas Melchardt; Lukas Weiss; Franz Josef Gassner; Nadja Zaborsky; Roland Geisberger; Kemal Catakovic; Tanja Hartmann; Lisa Pleyer; Daniela Voskova; Josef Thaler; Alois Lang; Michael Girschikofsky; Andreas Petzer; Richard Greil

doi:10.1007/s00277-018-3380-z

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Alexander Egle (First author), Michael Steurer, Thomas Melchardt (Co-author), Lukas Weiss (Co-author), Franz Josef Gassner (Co-author), Nadja Zaborsky (Co-author), Roland Geisberger (Co-author), Kemal Catakovic (Co-author), Tanja Hartmann (Co-author), Lisa Pleyer (Co-author), Daniela Voskova, Josef Thaler, Alois Lang, Michael Girschikofsky, Andreas Petzer, Richard Greil^* (Last author)

^*Corresponding author for this work

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article (Journal) › peer-review

11 Citations (Web of Science)

Original language	English
Pages (from-to)	1825-1839
Journal	ANNALS OF HEMATOLOGY
Volume	97
Issue number	10
DOIs	https://doi.org/10.1007/s00277-018-3380-z
Publication status	Published - 2018

Keywords

INTEGRATIVE GENOMICS VIEWER
MINIMAL RESIDUAL DISEASE
T-CELL SUBSETS
DOUBLE-BLIND
PLUS DEXAMETHASONE
MULTIPLE-MYELOMA
OPEN-LABEL
TRIAL
CYCLOPHOSPHAMIDE
THERAPY

Access to Document

10.1007/s00277-018-3380-z

Cite this

Egle, A., Steurer, M., Melchardt, T., Weiss, L., Gassner, F. J., Zaborsky, N., Geisberger, R., Catakovic, K., Hartmann, T., Pleyer, L., Voskova, D., Thaler, J., Lang, A., Girschikofsky, M., Petzer, A., & Greil, R. (2018). Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. ANNALS OF HEMATOLOGY , 97(10), 1825-1839. https://doi.org/10.1007/s00277-018-3380-z

Egle, Alexander ; Steurer, Michael ; Melchardt, Thomas et al. / Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. In: ANNALS OF HEMATOLOGY 2018 ; Vol. 97, No. 10. pp. 1825-1839.

@article{c79630cc45264550b81806a42826b724,

title = "Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.",

keywords = "INTEGRATIVE GENOMICS VIEWER, MINIMAL RESIDUAL DISEASE, T-CELL SUBSETS, DOUBLE-BLIND, PLUS DEXAMETHASONE, MULTIPLE-MYELOMA, OPEN-LABEL, TRIAL, CYCLOPHOSPHAMIDE, THERAPY",

author = "Alexander Egle and Michael Steurer and Thomas Melchardt and Lukas Weiss and Gassner, {Franz Josef} and Nadja Zaborsky and Roland Geisberger and Kemal Catakovic and Tanja Hartmann and Lisa Pleyer and Daniela Voskova and Josef Thaler and Alois Lang and Michael Girschikofsky and Andreas Petzer and Richard Greil",

note = "Egle, Melchardt, Weiss, Pleyer, Greil: Paracelsus Med Univ Salzburg, Oncol Ctr, Hematol & Med Oncol, Dept Internal Med 3, Salzburg, Austria; Petzer: Lehr-KH! barmh Schwestern Linz",

year = "2018",

doi = "10.1007/s00277-018-3380-z",

language = "English",

volume = "97",

pages = "1825--1839",

journal = "ANNALS OF HEMATOLOGY ",

issn = "0939-5555",

number = "10",

}

Egle, A, Steurer, M, Melchardt, T , Weiss, L , Gassner, FJ , Zaborsky, N , Geisberger, R, Catakovic, K, Hartmann, T, Pleyer, L, Voskova, D, Thaler, J, Lang, A, Girschikofsky, M, Petzer, A & Greil, R 2018, 'Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.', ANNALS OF HEMATOLOGY , vol. 97, no. 10, pp. 1825-1839. https://doi.org/10.1007/s00277-018-3380-z

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. / Egle, Alexander (First author); Steurer, Michael; Melchardt, Thomas (Co-author) et al.
In: ANNALS OF HEMATOLOGY , Vol. 97, No. 10, 2018, p. 1825-1839.

Research output: Contribution to journal › Original Article (Journal) › peer-review

TY - JOUR

T1 - Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

AU - Egle, Alexander

AU - Steurer, Michael

AU - Melchardt, Thomas

AU - Weiss, Lukas

AU - Gassner, Franz Josef

AU - Zaborsky, Nadja

AU - Geisberger, Roland

AU - Catakovic, Kemal

AU - Hartmann, Tanja

AU - Pleyer, Lisa

AU - Voskova, Daniela

AU - Thaler, Josef

AU - Lang, Alois

AU - Girschikofsky, Michael

AU - Petzer, Andreas

AU - Greil, Richard

N1 - Egle, Melchardt, Weiss, Pleyer, Greil: Paracelsus Med Univ Salzburg, Oncol Ctr, Hematol & Med Oncol, Dept Internal Med 3, Salzburg, Austria; Petzer: Lehr-KH! barmh Schwestern Linz

PY - 2018

Y1 - 2018

KW - INTEGRATIVE GENOMICS VIEWER

KW - MINIMAL RESIDUAL DISEASE

KW - T-CELL SUBSETS

KW - DOUBLE-BLIND

KW - PLUS DEXAMETHASONE

KW - MULTIPLE-MYELOMA

KW - OPEN-LABEL

KW - TRIAL

KW - CYCLOPHOSPHAMIDE

KW - THERAPY

U2 - 10.1007/s00277-018-3380-z

DO - 10.1007/s00277-018-3380-z

M3 - Original Article (Journal)

C2 - 29862437

SN - 0939-5555

VL - 97

SP - 1825

EP - 1839

JO - ANNALS OF HEMATOLOGY

JF - ANNALS OF HEMATOLOGY

IS - 10

ER -

Egle A, Steurer M, Melchardt T , Weiss L , Gassner FJ , Zaborsky N et al. Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. ANNALS OF HEMATOLOGY . 2018;97(10):1825-1839. doi: 10.1007/s00277-018-3380-z